RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Recordati Industria Chimica e Farmaceutica SpA Stock

Recordati Industria Chimica e Farmaceutica SpA ROE 2025

Recordati Industria Chimica e Farmaceutica SpA ROE

0.23

Ticker

REC.MI

ISIN

IT0003828271

WKN

A0EABR

In 2025, Recordati Industria Chimica e Farmaceutica SpA's return on equity (ROE) was 0.23, a 14.26% increase from the 0.2 ROE in the previous year.

Recordati Industria Chimica e Farmaceutica SpA Aktienanalyse

What does Recordati Industria Chimica e Farmaceutica SpA do?

Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide. Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology. Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions. Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia). Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative. In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers. In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas. Recordati Industria Chimica e Farmaceutica SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Recordati Industria Chimica e Farmaceutica SpA's Return on Equity (ROE)

Recordati Industria Chimica e Farmaceutica SpA's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Recordati Industria Chimica e Farmaceutica SpA's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Recordati Industria Chimica e Farmaceutica SpA's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Recordati Industria Chimica e Farmaceutica SpA’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Recordati Industria Chimica e Farmaceutica SpA stock

What is the ROE (Return on Equity) of Recordati Industria Chimica e Farmaceutica SpA this year?

The ROE of Recordati Industria Chimica e Farmaceutica SpA this year is 0.23 undefined.

How has the Return on Equity (ROE) of Recordati Industria Chimica e Farmaceutica SpA developed compared to the previous year?

The ROE of Recordati Industria Chimica e Farmaceutica SpA has increased by 14.26% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Recordati Industria Chimica e Farmaceutica SpA?

A high ROE indicates that Recordati Industria Chimica e Farmaceutica SpA generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Recordati Industria Chimica e Farmaceutica SpA?

A low ROE can indicate that Recordati Industria Chimica e Farmaceutica SpA is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Recordati Industria Chimica e Farmaceutica SpA affect the company?

A change in ROE (Return on Equity) of Recordati Industria Chimica e Farmaceutica SpA can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Recordati Industria Chimica e Farmaceutica SpA?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Recordati Industria Chimica e Farmaceutica SpA?

Some factors that can influence Recordati Industria Chimica e Farmaceutica SpA's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Recordati Industria Chimica e Farmaceutica SpA pay?

Over the past 12 months, Recordati Industria Chimica e Farmaceutica SpA paid a dividend of 1.17 EUR . This corresponds to a dividend yield of about 2.18 %. For the coming 12 months, Recordati Industria Chimica e Farmaceutica SpA is expected to pay a dividend of 1.25 EUR.

What is the dividend yield of Recordati Industria Chimica e Farmaceutica SpA?

The current dividend yield of Recordati Industria Chimica e Farmaceutica SpA is 2.18 %.

When does Recordati Industria Chimica e Farmaceutica SpA pay dividends?

Recordati Industria Chimica e Farmaceutica SpA pays a quarterly dividend. This is distributed in the months of June, December, June, December.

How secure is the dividend of Recordati Industria Chimica e Farmaceutica SpA?

Recordati Industria Chimica e Farmaceutica SpA paid dividends every year for the past 0 years.

What is the dividend of Recordati Industria Chimica e Farmaceutica SpA?

For the upcoming 12 months, dividends amounting to 1.25 EUR are expected. This corresponds to a dividend yield of 2.34 %.

In which sector is Recordati Industria Chimica e Farmaceutica SpA located?

Recordati Industria Chimica e Farmaceutica SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Recordati Industria Chimica e Farmaceutica SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Recordati Industria Chimica e Farmaceutica SpA from 11/20/2024 amounting to 0.6 EUR, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Recordati Industria Chimica e Farmaceutica SpA pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Recordati Industria Chimica e Farmaceutica SpA in the year 2024?

In the year 2024, Recordati Industria Chimica e Farmaceutica SpA distributed 1.17 EUR as dividends.

In which currency does Recordati Industria Chimica e Farmaceutica SpA pay out the dividend?

The dividends of Recordati Industria Chimica e Farmaceutica SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Recordati Industria Chimica e Farmaceutica SpA

Our stock analysis for Recordati Industria Chimica e Farmaceutica SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Recordati Industria Chimica e Farmaceutica SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.